Volume 63, Issue 1, Pages (July 2015)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 60, Issue 1, Pages (January 2014)
Volume 63, Issue 1, Pages (July 2015)
Volume 53, Issue 1, Pages (July 2010)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Volume 41, Issue 5, Pages (November 2004)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice  Parambir.
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Volume 51, Issue 6, Pages (December 2009)
The impact of hepatitis E in the liver transplant setting
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Volume 66, Issue 1, Pages 1-4 (January 2017)
Living donor liver transplantation: is the hype over?
European Association for the Study of the Liver  Journal of Hepatology 
Mesenchymal stromal cell therapy for liver diseases
Reply to: “DCD consensus and futility in liver transplantation”
The place of downstaging for hepatocellular carcinoma
Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial  David Houghton, Christian.
Volume 61, Issue 2, Pages (August 2014)
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Volume 69, Issue 5, Pages (November 2018)
Darius Moradpour, Arash Grakoui, Michael P. Manns 
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Volume 60, Issue 1, Pages (January 2014)
Volume 57, Issue 5, Pages (November 2012)
Volume 50, Issue 4, Pages (April 2009)
Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis – Overlapping or separate diseases?  George J.M. Webster, Stephen.
Estimation of Adipose Pools in Hemodialysis Patients From Anthropometric Measures  George A. Kaysen, Peter Kotanko, Fansan Zhu, Shubho R. Sarkar, Steven.
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Paul C. Adams, James C. Barton  Journal of Hepatology 
Chetana Lim, Chady Salloum, Daniel Azoulay
Immigration and viral hepatitis
The potential of induced pluripotent stem cell derived hepatocytes
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Immunological techniques in viral hepatitis
Changes in the 24-h plasma cortisol rhythm in patients with cirrhosis
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
Serum HBV pgRNA as a clinical marker for cccDNA activity
The use of hemospray in portal hypertensive bleeding; a case series
Volume 62, Issue 3, Pages (March 2015)
Volume 66, Issue 4, Pages (April 2017)
Shunt dysfunction: Is it suitable as the primary end point in transjugular intrahepatic portosystemic shunt trials?  Jingzhi Cai, Wengang Guo, Chuangye.
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
The relationship between age and fat infiltration in liver and muscle
Volume 64, Issue 2, Pages (February 2016)
Genetics of hepatocellular carcinoma: The next generation
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child
Presentation transcript:

Volume 63, Issue 1, Pages 174-182 (July 2015) Effect of aerobic exercise training dose on liver fat and visceral adiposity  Shelley E. Keating, Daniel A. Hackett, Helen M. Parker, Helen T. O’Connor, James A. Gerofi, Amanda Sainsbury, Michael K. Baker, Vivienne H. Chuter, Ian D. Caterson, Jacob George, Nathan A. Johnson  Journal of Hepatology  Volume 63, Issue 1, Pages 174-182 (July 2015) DOI: 10.1016/j.jhep.2015.02.022 Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Flowchart showing the study process. M, male; F, female; HI:LO, high intensity, low volume aerobic exercise; LO:HI, low to moderate intensity, high volume aerobic exercise; LO:LO, low to moderate intensity, low volume aerobic exercise; PLA, Placebo control group; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy. Journal of Hepatology 2015 63, 174-182DOI: (10.1016/j.jhep.2015.02.022) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Effect of 8weeks of exercise regimen on intrahepatic fat and visceral adipose tissue. Participants followed 8weeks of high intensity, low volume aerobic exercise (HI:LO), or low to moderate intensity, high volume aerobic exercise (LO:HI), or low to moderate intensity, low volume aerobic exercise (LO:LO), or control (PLA), which resulted in significant changes in (A) Intrahepatic lipid (IHL) and (B) visceral adipose tissue (VAT). Circles show individual percentage change from baseline and horizontal bars show mean group percentage change from baseline. *Significant treatment×time interaction (p<0.05). Journal of Hepatology 2015 63, 174-182DOI: (10.1016/j.jhep.2015.02.022) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions